Categories: Coronavirus Local

Moderna’s COVID-19 Vaccine Set For Final Trial Stage After ‘Promising’ Results

In this file photo taken on May 18, 2020, a syringe is pictured on an illustration representation of COVID-19, the disease caused by the novel coronavirus. Photo: JOEL SAGET / AFP

 

The US biotech firm Moderna said Tuesday it would enter the final stage of its human trials for its COVID-19 vaccine on July 27, after promising early results were published in a journal.

The Phase 3 trial will recruit 30,000 participants in the US, with half to receive the vaccine at 100 microgram dose levels, and the other half will receive a placebo.

It is designed to learn whether the vaccine can prevent infection by the SARS-CoV-2 virus, or, if people still get infected, whether it can prevent the infection progressing toward symptoms.

If they do get symptoms, the vaccine can still be considered a success if it stops severe cases of COVID-19.

The study should run until October 27, according to its page on clinicaltrials.gov.

The announcement came after the New England Journal of Medicine on Tuesday published results from the first stage of Moderna’s vaccine trial, which showed the first 45 participants all developed antibodies to the virus.

This file photo shows medical workers in Abuja preparing to test Nigerians for COVID-19. As of July 15, the pandemic had infected 33,616 and a total of over 13.2 million people globally, killing over 575,000 people.

 

Moderna is in pole position in the global race to find a vaccine against the coronavirus, which has infected more than 13.2 million people and killed 570,000.

China’s SinoVac is also at an advanced stage, Phase 2, while the Russian news agency TASS has announced Russian researchers have completed clinical trials on a vaccine, though they have not shared data.

Scientists caution that the first vaccines to come to market may not be the most effective or safest.



The Moderna vaccine belongs to a new class of vaccine that uses genetic material, in the form of RNA, to encode the information needed to grow the virus’ spike protein inside the human body, in order to trigger an immune response.

The spike protein is a part of the virus it uses to invade human cells, but by itself is relatively harmless.

The advantage of this technology is that it bypasses the need to manufacture viral proteins in the lab, shaving months off the standardization process and helping to ramp up mass production.

But no vaccines based on this platform have previously received regulatory approval.

AFP

oluchi

Disqus Comments Loading...

Recent Posts

  • Coronavirus
  • Headlines

Ondo Reports 95 Fresh COVID-19 Cases As Nigeria’s Infections Near 35, 000

    Ondo State on Thursday recorded ninety-five fresh COVID-19 cases as Nigeria's infections from the virus inched closer to…

7 hours ago
  • Sports

Barcelona Congratulate Real Madrid For Winning 2019/2020 La Liga Crown

    Barcelona have congratulated Real Madrid for winning the 2019/2020 La Liga title on Thursday after they (Real Madrid)…

8 hours ago
  • Sports

Why NFF Used PPG to Conclude 2019/2020 NPFL Season – Pinnick

  The Nigeria Football Federation (NFF) has explained why the Points-Per-Game (PPG) formula was adopted in concluding the 2019/2020 Nigeria…

8 hours ago
  • Business

NLNG Denies Withdrawal Of $1.05bn From Dividend Account

  The Nigeria Liquefied Natural Gas Limited (NLNG) has condemned the reports that it illegally withdrew the sum of $1.05…

9 hours ago
  • Sports

Man United Beat Crystal Palace To Keep Champions League Hopes Alive

  Manchester United beat Crystal Palace 2-0 to keep the pressure on Leicester after their top-four rivals defeated Sheffield United as the battle for…

9 hours ago
  • Politics

Buhari Warns Ministers, MDAs, Others Against Disrespecting National Assembly

  President Muhammadu Buhari has read the riot act to ministers and heads of the Ministries, Departments, and Agencies (MDAs)…

9 hours ago